A drug that has been demonstrated to slow the early stages of Alzheimer's disease has been given the go-light by health officials in the United States.
More than 6.5 million Americans are living with Alzheimer's disease, a degenerative brain ailment that impairs memory, thinking, and ultimately the ability to do even the most basic of tasks.
Although the root causes of Alzheimer's disease remain unknown, the disease is defined by neurodegenerative changes in the brain, such as the accumulation of amyloid beta plaques and neurofibrillary (tau) tangles, which ultimately lead to the death of neurons and the disruption of synapses between them. Memory and cognition are impacted by these shifts.
Leqembi is an Alzheimer's disease medication that has been given the green light by the U.S. Food and Drug Administration through the Accelerated Approval process. In the fight against Alzheimer's disease, Leqembi is the second drug of a new class to be approved that directly addresses the underlying pathophysiology of the condition.
The development of these drugs is a major step forward in the search for effective treatments for Alzheimer's disease.
It can take years to determine if a new medicine improves functional recovery, emotions, or performance. In the setting of a particular condition, a favorable therapeutic result that has clinical significance is referred to as "clinical benefit."
According to Billy Dunn, M.D., head of the Office of Neuroscience in the FDA's Center for Drug Evaluation and Research, "Alzheimer's disease enormously incapacitates the lives of those suffering from it and has terrible impacts on their loved ones."This therapy is the most recent attempt to address the root cause of Alzheimer's rather than just the symptoms.
In 1992, FDA implemented Accelerated Approval standards because measuring a drug's anticipated clinical benefit may take a long time. These laws permitted surrogate endpoint-based medication approvals for serious illnesses with unmet medical needs. Substitute targets helped the FDA approve some medications faster.
The FDA authorised Leqembi through the Accelerated Approval pathway, which allows the FDA to recommend medications for serious illnesses with an unfulfilled need and a surrogate endpoint that is likely to show a therapeutic benefit to patients. The government expects to receive the results of Phase 3 randomised, controlled clinical trial that confirmed the drug's clinical benefit.
In a field that is accustomed to the failure of experimental treatments for an incurable ailment, the drug Leqembi, which was developed by the Japanese company Eisai and its US partner Biogen, is a remarkable triumph.
Although the medicine is only expected to slow cognitive deterioration by a few months at most, its proponents insist that it will have a positive impact on patient's quality of life, nonetheless.
St. Louis-based neurologist Dr. Joy Snider emphasised that this medication is not a panacea. Though it doesn't stop patients from growing worse, it slows the disease. That may potentially add six months to a year to a person's driving privileges.
Dr. Snider highlighted that there are drawbacks to the medication, including the necessity for treatments twice a month and the possibility of adverse effects such as brain swelling and haemorrhage. Accelerated approval by the FDA means the drug can be sold to the public before it is safe and effective in treating patients. Government watchdogs and congressional investigators are increasingly looking into the agency's use of that shortcut.
There is a potential for infusion-related responses with Leqembi, including flu-like symptoms, nausea, vomiting, and changes in blood pressure. Infusion reactions and headaches were the most often reported adverse effects of Leqembi.
Leqembi's label indicates it should be used to treat Alzheimer's disease. Patients with mild cognitive impairment or mild dementia are included in the labelling recommendations for Leqembi since this is the population examined in clinical studies. The labelling also warns against starting treatment before or after the phases of sickness that were evaluated, as no data exist on the safety or effectiveness of doing so.
The average cost of the medicine over a year of treatment would be $26,500. According to Eisai, the drug's pricing represents its value concerning increased patient well-being and decreased carer stress.
The annual value was estimated by the manufacturer to be $37,000, however, the firm justified the lower price by claiming it was necessary to keep expenses down for patients and insurance. A medicine's price must be below $20,000 for it to be considered cost-effective, according to an independent committee that evaluates drug value.
Alzheimer's slowly destroys brain regions vital for memory, logic, communication, and daily functions, and it affects around 6 million Americans and many more across the world.
The FDA's green light came from one intermediate-stage research in 850 participants showing early indications of Alzheimer's and testing positive for a specific form of brain plaque.
Share This Post On
0 comments
Leave a comment
You need to login to leave a comment. Log-in
